New cocktail of drugs and targeted procedure aims to control liver cancer
NCT ID NCT04472767
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of three drugs (cabozantinib, ipilimumab, and nivolumab) plus a procedure called TACE in 35 people with liver cancer that cannot be cured by surgery or transplant. The goal is to see if this approach can stop the cancer from growing for at least 6 months. Participants will receive the drugs and up to 3 TACE sessions over several weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib, ipilimumab, nivolumab, and transarterial chemoembolization (TACE)
What this could lead to
If successful, this combination could offer a new treatment option to control liver cancer and extend life for patients who cannot have surgery or a transplant.
What could go wrong
This is an early phase 2 trial with only 35 participants, so results may not apply to everyone. The combination of drugs and TACE can cause serious side effects, and it is not yet known if it works better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
RECRUITINGOrange, California, 92868, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••